Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,362.5,17,676 shares at DKK 1,615,949 shares at DKK 1,948,25,635 shares at DKK 2,070,6,1
Motley Fool Press Release.
Investing.com -- Genmab reported a 22% rise in revenue for the first nine months of 2026 on Thursday, driven by higher royalties from Darzalex and Kesimpta and stronger sales of its cancer drug Epkinly. The Danish biotech maintained its full-year guidance.
Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Six oral presentations include first data disclosure from the Phase 3 EPCORE® DLBCL-4 study evaluating epcoritamab in combination with lenalidomide in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Genmab A/S (Nasdaq: GMAB) announced today that 22 abst
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Tipranks Press Release.
Genmab stock surged on strong Phase 3 cancer data, but valuation and patent risks remain. Click here to read this recent analysis of GMAB stock.
U.S.-traded shares of Genmab jumped 28% Wednesday after the Danish drugmaker said its experimental drug, petosemtamab, cut the risk of death by half in a late-stage study of patients with head and neck cancer. Patients got the drug alongside Merck's blockbuster immunotherapy Keytruda, and were compa
Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
Genmab (GMAB) stock surges as head and neck cancer cuts death risk by 50%, with Merck’s (MRK) Keytruda sending Bicara Therapeutics (BCAX) lower. Read more here.
Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC), with responses observed across HPV-positive and HPV-negative diseasePhase 3 program in 1L HNSCC is ongoing, with topline data anticipated later this year Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2
Genmab and Incyte team up on a Phase 1/2 colorectal cancer trial targeting KRAS G12D.
This is the newest page. Registered accounts read further back.